Company Description
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance.
Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures.
In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally.
NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.
| Country | United States |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Doron Besser |
Contact Details
Address: 969 Pruitt Ave Tyler, Texas 77569 United States | |
| Phone | 914 233 3004 |
| Website | nanovibronix.com |
Stock Details
| Ticker Symbol | NAOV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326706 |
| CUSIP Number | 63008J108 |
| ISIN Number | US63008J6038 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Dr. Doron Robert Besser M.D. | Chief Executive Officer and Director |
| Stephen R. Brown CPA | Chief Financial Officer |
| Dr. Harold Jacob M.D. | Chief Medical Officer |
| Lindsey Harrison | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 9, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 4, 2025 | 8-K | Current Report |
| May 20, 2025 | 10-Q | Quarterly Report |
| May 19, 2025 | SCHEDULE 13G | Filing |
| May 16, 2025 | 8-K | Current Report |
| May 16, 2025 | 424B4 | Prospectus |
| May 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | EFFECT | Notice of Effectiveness |
| May 14, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |